Last updated: September 21, 2026
Vandetanib is a niche oncology product with declining strategic importance for AstraZeneca as selective RET inhibitors capture treatment share in RET-altered thyroid cancer. FDA approval, orphan-drug exclusivity, and early treatment demand created a protected market for Caprelsa, but the commercial opportunity remained limited by the rarity of medullary thyroid cancer, cardiovascular monitoring requirements, and competition from cabozantinib, selpercatinib, and pralsetinib. AstraZeneca does not report Caprelsa revenue as a standalone line item, preventing a reliable public product-level revenue series. [1][2]
What is vandetanib approved to treat?
Vandetanib is an oral kinase inhibitor marketed in the United States as Caprelsa. The FDA approved it on April 6, 2011, for adults with symptomatic or progressive medullary thyroid cancer that is unresectable locally advanced or metastatic. The label limits use to patients for whom the benefit of treatment outweighs the risk of QT prolongation. [1]
The drug inhibits several kinases, including:
- RET, the principal disease-relevant target in medullary thyroid cancer
- VEGFR-2 and VEGFR-3
- EGFR
The standard FDA-labeled dose is 300 mg once daily. Vandetanib has a long terminal half-life of approximately 19 days, which can complicate management of adverse events and drug interactions. [1]
What is the FDA regulatory status of Caprelsa?
Caprelsa received FDA approval through the standard new drug application pathway with orphan-drug designation. Its label includes a boxed warning for QT prolongation, torsades de pointes, and sudden death. The product is distributed under a restricted program, the Caprelsa Risk Evaluation and Mitigation Strategy, which requires prescriber and pharmacy certification. [1]
The FDA approval was based principally on the phase 3 ZETA trial. Vandetanib improved progression-free survival compared with placebo in patients with advanced medullary thyroid cancer, although the trial did not establish a statistically significant overall-survival benefit in the primary analysis. [3]
How large is the vandetanib market?
The addressable market is structurally small. Medullary thyroid cancer represents roughly 3% to 5% of thyroid cancers, and only a subset of patients develop advanced disease requiring systemic therapy. The commercial market is concentrated in the United States, Europe, Japan, and selected other developed markets.
Market demand is constrained by four factors:
- Medullary thyroid cancer is rare.
- Many patients with indolent disease do not require immediate systemic treatment.
- Vandetanib has clinically meaningful cardiac and gastrointestinal toxicity.
- Selective RET inhibitors offer a more targeted treatment option for patients with RET-altered disease.
The product can still be relevant for patients who lack an actionable RET alteration, require an established multikinase inhibitor, or cannot access newer RET-directed drugs. Its use is less attractive when a patient has a known RET alteration and can receive selpercatinib or pralsetinib.
What is the financial trajectory for vandetanib?
AstraZeneca does not disclose Caprelsa revenue separately in its annual reports. The product is included within broader portfolio or therapeutic-area reporting, if reported at all. Public filings therefore do not support a defensible standalone revenue forecast or a verified annual sales history. [2]
The commercial trajectory can be divided into four periods:
| Period |
Market condition |
Financial implication |
| 2011-2013 |
FDA launch and orphan-market adoption |
Initial uptake supported by limited systemic options |
| 2014-2018 |
Established use in advanced medullary thyroid cancer |
Stable niche revenue, limited volume expansion |
| 2018-2020 |
Loss of U.S. orphan exclusivity and greater treatment competition |
Pricing and volume pressure increased |
| 2020 onward |
Selective RET inhibitors and generic-entry risk |
Declining strategic value and reduced growth potential |
Caprelsa never developed the scale of a major AstraZeneca oncology brand. Its revenue ceiling was limited by disease prevalence, a narrow labeled population, restricted distribution, and treatment discontinuation from adverse events.
The financial profile is therefore better characterized as a mature orphan oncology asset than as a growth product. Any residual value is likely tied to established physician familiarity, global registrations, supply reliability, and use in patients who are not candidates for newer RET inhibitors.
When did vandetanib lose exclusivity?
Vandetanib’s U.S. orphan-drug exclusivity ended seven years after FDA approval, on or around April 6, 2018. Orphan exclusivity blocks FDA approval of the same drug for the same indication but does not prevent all competing products or off-label use. [1][4]
Patent protection is separate from orphan exclusivity. Patent term depends on the particular compound, formulation, use, and jurisdiction. The relevant patent estate has included AstraZeneca patents covering quinazoline compounds and therapeutic uses. The lead composition patent associated with vandetanib has generally been reported as expiring in the early-to-mid-2020s, subject to patent-term adjustment, terminal disclaimers, and jurisdiction-specific calculations.
A definitive current launch analysis must distinguish:
- FDA regulatory exclusivity
- Orange Book-listed patents
- Unlisted method-of-use or manufacturing patents
- Pediatric exclusivity
- Patent-term adjustment
- Patent settlements and licenses
Vandetanib has no biosimilar pathway because it is a chemically synthesized small molecule. Competitive entry would occur through an abbreviated new drug application, not a biosimilar application.
What patents protect vandetanib?
The core patent estate was developed by AstraZeneca and related entities and centers on quinazoline kinase inhibitors, including vandetanib. The protection has historically included:
- Composition-of-matter claims covering substituted quinazoline compounds
- Pharmaceutical-composition claims
- Therapeutic-use claims for cancer
- Manufacturing and intermediate claims
- Potential formulation or dosage-regimen claims
The principal commercial barrier was the compound patent. Once core compound protection expired or became vulnerable, formulation and method-of-use patents would have had less ability to preserve broad market exclusivity because generic applicants could seek approval for a non-infringing label or rely on a legally permissible carve-out.
The FDA Orange Book is the controlling public source for patents listed against the approved U.S. product. Orange Book listings can change through delisting, expiration, patent disputes, and FDA updates. [5]
How strong is the vandetanib patent estate?
The estate is moderate rather than strong by current specialty-pharmaceutical standards.
Its strengths are:
- A first-in-class or early-entry position in medullary thyroid cancer
- A defined chemical compound with historical patent protection
- Orphan-drug exclusivity during the critical launch period
- A narrow disease indication that reduced immediate competitive crowding
Its weaknesses are:
- The product’s core value is concentrated in a single rare indication
- Generic applicants can often avoid method-of-use claims through label carve-outs
- Cardiac-risk labeling limits commercial attractiveness
- Newer RET inhibitors reduce the value of broad thyroid-cancer claims
- No biologic manufacturing barrier protects the product
Manufacturing complexity is not expected to create a durable barrier comparable with monoclonal antibodies, cell therapies, or complex injectable formulations. Vandetanib is an oral small molecule, making chemical synthesis and tablet manufacturing comparatively accessible to established generic companies.
Which companies are challenging vandetanib?
The competitive threat comes from both branded products and potential generic manufacturers.
Branded competitors
| Product |
Company |
Target profile |
Competitive effect |
| Caprelsa |
AstraZeneca |
Multikinase inhibitor including RET and VEGFR |
Established treatment option |
| Cometriq |
Exelixis |
Multikinase inhibitor including MET, VEGFR, and RET |
Direct systemic competitor |
| Retevmo |
Eli Lilly |
Selective RET inhibitor |
Strong competitor in RET-altered disease |
| Gavreto |
Blueprint Medicines/Roche |
Selective RET inhibitor |
Competed in RET-altered disease; U.S. commercial status changed after Roche ended its collaboration |
| Cabozantinib generic or branded versions |
Multiple companies |
Multikinase inhibitor |
Expands treatment alternatives |
Selpercatinib is the most important strategic competitor because it selectively inhibits RET and has approvals in RET-mutant medullary thyroid cancer and other RET-driven tumors. Its positioning can displace vandetanib in biomarker-defined patients. [6]
Pralsetinib also entered the RET-inhibitor market, although commercialization and regulatory status have evolved by territory. Its market impact has been less durable than initially expected in some regions.
What patent litigation and Paragraph IV risks affect vandetanib?
A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. Publicly visible market risk depends on whether an ANDA applicant has filed such a certification, whether the NDA holder sued within 45 days, and whether litigation triggered a 30-month stay under the Hatch-Waxman Act.
The principal risks for vandetanib are:
- A generic ANDA supported by a Paragraph IV certification
- A section viii label carve-out for method-of-use claims
- Patent expiration without a settlement
- An authorized generic or licensed generic launch
- Commercial entry after loss of core composition protection
No reliable public conclusion should be drawn from the mere presence of an Orange Book patent. A patent can remain listed while being weak, expired, non-infringing, or irrelevant to the generic applicant’s proposed label.
The commercial risk is greater if a generic can launch with a broad label covering the principal indication. A narrow carve-out may produce less substitution because medullary thyroid cancer treatment is specialist-driven and pharmacy substitution can depend on the exact approved indication and payer policy.
What generic launch scenarios exist for vandetanib?
Three launch scenarios are commercially plausible.
1. At-risk generic launch
A generic company launches before final patent resolution after issuing a Paragraph IV challenge. This creates immediate price erosion and exposes the entrant to damages if the patent holder prevails.
2. Agreed entry date
A patent settlement permits entry on a negotiated date. Such agreements may include licensed entry, an authorized generic, or restrictions tied to specific patents and indications. The economic result depends on the settlement date and the number of entrants.
3. Post-expiration entry
Generic companies wait until the relevant composition patents expire. This produces the lowest litigation risk but can still cause substantial price erosion because specialty oral oncology products often experience rapid share loss after multiple generic entries.
Vandetanib’s narrow market may support only a small number of entrants. That can moderate price erosion compared with high-volume primary-care drugs, but specialist demand is also limited, reducing the absolute value of market entry.
How does vandetanib compare with selpercatinib and cabozantinib?
| Factor |
Vandetanib |
Selpercatinib |
Cabozantinib |
| Target profile |
Multikinase |
Selective RET |
Multikinase |
| Main thyroid-cancer use |
Advanced medullary thyroid cancer |
RET-altered thyroid cancers |
Advanced thyroid and other cancers |
| Biomarker dependence |
Not strictly biomarker-dependent |
RET alteration is central |
Not strictly biomarker-dependent |
| Cardiac risk |
QT prolongation is a major concern |
Different safety profile, with hypertension and liver-related monitoring |
Broad multikinase toxicity profile |
| Commercial position |
Mature niche product |
Premium targeted competitor |
Established alternative |
| Generic or biosimilar risk |
Small-molecule generic risk |
Patent-protected branded product |
Small-molecule generic risk over time |
Vandetanib retains value where broad multikinase activity is clinically useful or where selective RET therapy is unavailable. Its long-term competitive position is weaker in patients with confirmed RET-driven disease.
What licensing deals affect vandetanib?
AstraZeneca developed and commercialized Caprelsa. Publicly disclosed commercialization arrangements have been less central to the product’s market identity than for many newer oncology assets. The major commercial issue is AstraZeneca’s continued ownership and management of an aging, low-volume product rather than a transformative licensing transaction.
By contrast, newer RET products have involved important partnerships. Roche’s collaboration with Blueprint Medicines around pralsetinib affected global commercialization and later market strategy. Lilly’s acquisition of Loxo Oncology brought selpercatinib into a larger oncology portfolio. These transactions strengthened the competitive resources behind selective RET inhibition. [7][8]
What revenue exposure does vandetanib create for AstraZeneca?
Vandetanib represents limited direct revenue exposure for AstraZeneca relative to products such as Tagrisso, Imfinzi, Farxiga, and Calquence. The primary financial risks are:
- Revenue decline after generic entry
- Manufacturing and distribution costs in a low-volume product
- Continuing pharmacovigilance and REMS obligations
- Price concessions to government and institutional buyers
- Potential inventory write-downs if market share falls sharply
The opportunity is defensive rather than expansionary. AstraZeneca can preserve residual revenue through global registrations, consistent supply, and specialist adoption, but the product has limited potential to regain growth without a new indication or materially improved clinical positioning.
Key Takeaways
- Vandetanib is a mature oral oncology product for unresectable or metastatic medullary thyroid cancer.
- FDA approval occurred on April 6, 2011; U.S. orphan exclusivity ended around April 6, 2018.
- AstraZeneca does not separately disclose Caprelsa revenue, so product-level financial forecasts cannot be verified from public filings.
- The commercial market is small and concentrated in a rare cancer population.
- Selpercatinib is the principal strategic threat because it selectively targets RET.
- Generic entry, rather than biosimilar competition, is the relevant post-exclusivity risk.
- The patent estate has greater value in the core compound claims than in formulation or method-of-use claims.
- Long-term value is likely to decline as selective RET inhibitors gain share and generic manufacturers enter.
FAQs
Is vandetanib still FDA approved?
Yes. Caprelsa remains FDA approved for adults with symptomatic or progressive unresectable locally advanced or metastatic medullary thyroid cancer when the benefits outweigh QT-prolongation risk. [1]
Is vandetanib a RET inhibitor?
Yes. Vandetanib inhibits RET, but it is a multikinase inhibitor that also affects VEGFR and EGFR. Selpercatinib is more selective for RET.
Does vandetanib have biosimilar competition?
No. Vandetanib is a small-molecule chemical drug. Competition would come through generic drug applications, not the FDA biosimilar pathway.
What is the main commercial threat to Caprelsa?
The main threat is the combination of selective RET inhibitors, particularly selpercatinib, and eventual generic competition after relevant patent barriers expire.
Does AstraZeneca report Caprelsa sales separately?
No. AstraZeneca’s public financial reporting does not provide a dependable standalone revenue series for Caprelsa. [2]
References
-
U.S. Food and Drug Administration. (2023). Caprelsa (vandetanib) prescribing information. FDA.
-
AstraZeneca PLC. (2024). Annual report and Form 20-F 2023. AstraZeneca.
-
Wells, S. A., Jr., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., et al. (2012). Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. Journal of Clinical Oncology, 30(2), 134-141.
-
U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
-
U.S. Food and Drug Administration. (2022). Retevmo (selpercatinib) prescribing information. FDA.
-
Roche. (2023). Roche provides update on Gavreto collaboration and U.S. commercialization. Roche.
-
Eli Lilly and Company. (2024). Annual report 2023. Eli Lilly and Company.
